ProQR (0PQ) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0PQ Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

ProQR

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0PQ Stock 12 Month Forecast

Average Price Target

€7.60

▲(369.05% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for ProQR in the last 3 months. The average price target is €7.60 with a high forecast of €10.52 and a low forecast of €2.63. The average price target represents a 369.05% change from the last price of €1.62.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","11":"€11","2.75":"€2.75","5.5":"€5.5","8.25":"€8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10.52111988,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.59858658,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.63027997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.601,2.287163067692308,2.9733261353846157,3.6594892030769235,4.345652270769231,5.03181533846154,5.717978406153847,6.404141473846155,7.090304541538463,7.77646760923077,8.462630676923078,9.148793744615386,9.834956812307695,{"y":10.52111988,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.601,2.0623528138461538,2.5237056276923076,2.9850584415384613,3.446411255384615,3.9077640692307694,4.369116883076924,4.8304696969230765,5.291822510769231,5.753175324615385,6.214528138461539,6.6758809523076925,7.137233766153846,{"y":7.59858658,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.601,1.6801753823076924,1.7593507646153845,1.838526146923077,1.9177015292307693,1.9968769115384615,2.076052293846154,2.1552276761538463,2.2344030584615386,2.3135784407692306,2.392753823076923,2.4719292053846154,2.5511045876923077,{"y":2.63027997,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.683,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.792,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.874,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.763,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.276,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.694,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.303,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.265,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.373,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.296,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.342,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.601,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€10.52

Average Price Target€7.60

Lowest Price Target€2.63

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kostas Biliouris

Oppenheimer

€1.59→€7.89

Buy

387.09%

Upside

Reiterated

07/06/26

Oppenheimer Reaffirms Their Buy Rating on ProQR (PRQR)

Ananda Ghosh

H.C. Wainwright

€10.52

Buy

549.45%

Upside

Reiterated

06/29/26

Analysts' Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)

Ryan Deschner

Raymond James

€12.27→€8.77

Buy

441.21%

Upside

Reiterated

06/26/26

ProQR Therapeutics price target lowered to $10 from $14 at Raymond JamesProQR Therapeutics price target lowered to $10 from $14 at Raymond James

Catherine Novack

JonesTrading

€9.64→€8.77

Buy

441.21%

Upside

Reiterated

06/26/26

ProQR Therapeutics price target lowered to $10 from $11 at JonesResearchProQR Therapeutics price target lowered to $10 from $11 at JonesResearch

Keay Nakae

Chardan Capital

€3.51→€2.63

Buy

62.36%

Upside

Reiterated

06/25/26

ProQR Therapeutics price target lowered to $3 from $4 at ChardanProQR Therapeutics price target lowered to $3 from $4 at Chardan

Steven Seedhouse

Cantor Fitzgerald

€7.01

Buy

332.97%

Upside

Reiterated

04/14/26

Analysts Offer Insights on Healthcare Companies: ProQR (NASDAQ: PRQR), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Carlsmed, Inc. (NASDAQ: CARL)

Jonathan Wolleben

Citizens JMP

€7.01

Buy

332.97%

Upside

Reiterated

03/12/26

Gavin Clark-Gartner

Evercore ISI

€4.38

Buy

170.60%

Upside

Reiterated

12/17/25

Evercore ISI Remains a Buy on ProQR (PRQR)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kostas Biliouris

Oppenheimer

€1.59→€7.89

Buy

387.09%

Upside

Reiterated

07/06/26

Oppenheimer Reaffirms Their Buy Rating on ProQR (PRQR)

Ananda Ghosh

H.C. Wainwright

€10.52

Buy

549.45%

Upside

Reiterated

06/29/26

Analysts' Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)

Ryan Deschner

Raymond James

€12.27→€8.77

Buy

441.21%

Upside

Reiterated

06/26/26

ProQR Therapeutics price target lowered to $10 from $14 at Raymond JamesProQR Therapeutics price target lowered to $10 from $14 at Raymond James

Catherine Novack

JonesTrading

€9.64→€8.77

Buy

441.21%

Upside

Reiterated

06/26/26

ProQR Therapeutics price target lowered to $10 from $11 at JonesResearchProQR Therapeutics price target lowered to $10 from $11 at JonesResearch

Keay Nakae

Chardan Capital

€3.51→€2.63

Buy

62.36%

Upside

Reiterated

06/25/26

ProQR Therapeutics price target lowered to $3 from $4 at ChardanProQR Therapeutics price target lowered to $3 from $4 at Chardan

Steven Seedhouse

Cantor Fitzgerald

€7.01

Buy

332.97%

Upside

Reiterated

04/14/26

Analysts Offer Insights on Healthcare Companies: ProQR (NASDAQ: PRQR), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Carlsmed, Inc. (NASDAQ: CARL)

Jonathan Wolleben

Citizens JMP

€7.01

Buy

332.97%

Upside

Reiterated

03/12/26

Gavin Clark-Gartner

Evercore ISI

€4.38

Buy

170.60%

Upside

Reiterated

12/17/25

Evercore ISI Remains a Buy on ProQR (PRQR)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ProQR

3 Months

Steven SeedhouseCantor Fitzgerald

Success Rate

5/9 ratings generated profit

Average Return

-2.67%

Copying Steven Seedhouse's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of -2.67% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

10/18 ratings generated profit

Average Return

+10.78%

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +10.78% per trade.

2 Years

Steven SeedhouseCantor Fitzgerald

Success Rate

3/9 ratings generated profit

Average Return

-1.30%

Copying Steven Seedhouse's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -1.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0PQ Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0PQ has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0PQ average Analyst price target in the past 3 months is 7.60.

Each month's total comprises the sum of three months' worth of ratings.

0PQ Financial Forecast

0PQ Earnings Forecast

Next quarter’s earnings estimate for 0PQ is -€0.11 with a range of -€0.16 to -€0.07. The previous quarter’s EPS was -€0.13. 0PQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 0PQ has Performed in-line its overall industry.

0PQ Sales Forecast

Next quarter’s sales forecast for 0PQ is €3.99M with a range of €0.00 to €5.00M. The previous quarter’s sales results were €2.08M. 0PQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 0PQ has Performed in-line its overall industry.

0PQ Stock Forecast FAQ

What is DE:0PQ’s average 12-month price target, according to analysts?

Based on analyst ratings, ProQR Therapeutics BV’s 12-month average price target is 7.60.

What is DE:0PQ’s upside potential, based on the analysts’ average price target?

ProQR Therapeutics BV has 369.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ProQR Therapeutics BV a Buy, Sell or Hold?

ProQR Therapeutics BV has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is ProQR Therapeutics BV’s share price target?

The average share price target for ProQR Therapeutics BV is 7.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €10.52 ,and the lowest forecast is €2.63. The average share price target represents 369.05% Increase from the current price of €1.62.

What do analysts say about ProQR Therapeutics BV?

ProQR Therapeutics BV’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of ProQR Therapeutics BV?

To buy shares of DE:0PQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

ProQR (0PQ) Stock Forecast & Price Target

0PQ Analyst Ratings

0PQ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ProQR

0PQ Analyst Recommendation Trends

0PQ Financial Forecast

0PQ Earnings Forecast

0PQ Sales Forecast

0PQ Stock Forecast FAQ

Detailed List of Analyst Forecasts